Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and… Read more
Nantong Jinghua Pharmaceutical Co Ltd - Asset Resilience Ratio
Nantong Jinghua Pharmaceutical Co Ltd (002349) has an Asset Resilience Ratio of 13.26% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Nantong Jinghua Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Nantong Jinghua Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥462.59 Million | 13.26% |
| Total Liquid Assets | CN¥462.59 Million | 13.26% |
Asset Resilience Insights
- Moderate Liquidity: Nantong Jinghua Pharmaceutical Co Ltd has 13.26% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Nantong Jinghua Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nantong Jinghua Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Nantong Jinghua Pharmaceutical Co Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Nantong Jinghua Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.18% | CN¥105.16 Million | CN¥3.30 Billion | -6.79pp |
| 2023-12-31 | 9.97% | CN¥317.69 Million | CN¥3.19 Billion | +5.87pp |
| 2022-12-31 | 4.11% | CN¥124.95 Million | CN¥3.04 Billion | -2.56pp |
| 2021-12-31 | 6.67% | CN¥213.36 Million | CN¥3.20 Billion | +3.04pp |
| 2020-12-31 | 3.64% | CN¥114.74 Million | CN¥3.16 Billion | +2.40pp |
| 2019-12-31 | 1.23% | CN¥36.27 Million | CN¥2.94 Billion | +0.36pp |
| 2018-12-31 | 0.87% | CN¥29.64 Million | CN¥3.40 Billion | -- |